Reviewer’s report

Title: Immunosuppressive Glycodelin A is an independent marker for poor prognosis in endometrial cancer

Version: 1 Date: 10 August 2013

Reviewer: Anjali Karande

Reviewer’s report:

In the last few years there have been contradictory reports on glycodelin (Gd) being a prognostic marker for endometrial cancers. The above manuscript throws light on why the observed discrepancy.

The authors obtained 292 endometrial cancer tissue samples post surgery. The synthesis of Gd by the tumor cells was confirmed with in situ hybridization experiments. No difference was found between the levels of Gd mRNA and the different stages of cancer. The tissue sections were then subjected to semi-quantitative immunohistochemical analyses using two different antibodies, one that recognizes the glycodelin protein backbone and the other, the differential glycans on glycodelin isoforms to assess the impact on patient outcome. They conclude that there is a negative correlation between the prognosis of the patients and their tissue levels of GdA, the isoform with immunosuppressive activity but not the other isoforms. This study on endometrial cancer is in agreement with the Authors’ recent report in 2012 on, glycodelin: a prognostic marker in ovarian cancer.

The above study is an impressive one, carried out meticulously with a significantly high number of endometrial cancer tissue samples with data on each patient’s follow-up over several years. Data are well presented and discussed appropriately. The methodologies adopted are standard ones and relevant to the objectives of the study.

Level of interest: An article whose findings are important to those with closely related research interests

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

I declare that I have no competing interests